Recent breakthroughs in hematological research have identified ABCD1 inhibition in AML as a highly promising therapeutic strategy. Acute myeloid leukemia (AML) cells possess a unique metabolic flexibility that supports their aggressive growth and resistance to conventional treatments. While clinicians have long understood mitochondrial lipid oxidation, this study highlights the critical role of peroxisomal fatty acid oxidation (pFAO) in leukemia maintenance. Researchers discovered that AML cells significantly upregulate the peroxisomal transporter ABCD1 compared to healthy hematopoietic cells.

The Mechanism of ABCD1 Inhibition in AML

ABCD1 acts as a primary gatekeeper for the import of very-long-chain fatty acids (VLCFAs) into peroxisomes. Consequently, the loss of ABCD1 disrupts lipid homeostasis and prevents the necessary breakdown of these fats. When scientists used genetic silencing or the pharmacological inhibitor eicosenol, the resulting ABCD1 inhibition in AML led to a toxic accumulation of VLCFAs. Specifically, this buildup triggers selective cell death in leukemic blasts both in vitro and in vivo models. Furthermore, the study demonstrates that normal progenitor cells remain viable because they can adapt by upregulating glycolysis, whereas AML cells lack this metabolic flexibility.

In murine models, the administration of eicosenol significantly reduced leukemia burden and prolonged overall survival. Notably, the treatment showed no evidence of systemic toxicity, which suggests a high safety profile for future clinical applications. Therefore, targeting ABCD1 offers a double advantage: it strikes at a specific metabolic vulnerability of cancer cells while preserving the health of normal blood-forming cells. These findings establish ABCD1 as a crucial regulator of pFAO and a valid novel target for anti-leukemic therapy.

Frequently Asked Questions

How does ABCD1 inhibition specifically target leukemia cells?

Leukemia cells rely heavily on peroxisomal fatty acid oxidation for energy and lipid homeostasis. Inhibiting ABCD1 blocks the entry of essential fatty acids into peroxisomes, causing a toxic accumulation that triggers apoptosis only in the malignant cells.

Why are healthy blood cells unaffected by this treatment?

Healthy hematopoietic progenitor cells possess greater metabolic plasticity. Unlike AML cells, normal progenitors can survive by shifting their energy production to glycolysis when fatty acid oxidation is blocked.

What is the potential of eicosenol in AML therapy?

Eicosenol is a pharmacological inhibitor that effectively targets ABCD1. In preclinical animal studies, it has shown the ability to reduce tumor burden and extend survival without causing significant side effects or toxicity.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

1. Parfenova EN et al. Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells. Blood. 2026 Feb 26. doi: undefined. PMID: 41746867.


2. Tcheng M, et al. Very long chain fatty acid metabolism is required in acute myeloid leukemia. Blood. 2021;137(25):3518–3532.


3. Samudio I, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010;120(1):142-156.